← back to search

Malinda Itchins

Australian Research Council · AU
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, Lung Cancer Research Studies, and Cancer Immunotherapy and Biomarkers.
h-index
16
citations
982
works
86
NIH funding
primary concept
email

Recent publications

Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy Analysis
International Journal of Molecular Sciences 2024cited by 12position: middledoi
The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Lymphocyte-to-Monocyte Ratio (LMR) as Biomarkers in Resected Pancreatic Cancer
Journal of Clinical Medicine 2023cited by 41position: middledoi
Phase II, double blind, placebo controlled, multi-site study to evaluate the safety, feasibility and desirability of conducting a phase III study of anamorelin for anorexia in people with small cell lung cancer: A study protocol (LUANA trial)
PLoS ONE 2023cited by 4position: middledoi
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer
Nature Medicine 2022cited by 178position: middledoi
Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors
Lung Cancer 2021cited by 48position: middledoi
Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program
Therapeutic Advances in Medical Oncology 2021cited by 44position: middledoi
EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non–Small Cell Lung Cancer
Clinical Lung Cancer 2021cited by 37position: middledoi
Plasma pre-treatment T790M relative allelic frequency in patients with advanced EGFR-mutated non-small cell lung cancer predicts treatment response to subsequent-line osimertinib
Translational Lung Cancer Research 2021cited by 11position: middledoi
ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors
Human Pathology 2018cited by 54position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Anthony J. Gill · The University of Sydney4 papers (2018–2023)Stephen Clarke · Carnegie Mellon University4 papers (2021–2023)Steven Kao · Chris O’Brien Lifehouse3 papers (2021–2021)Nick Pavlakis · University of Sydney3 papers (2021–2023)Jaswinder S. Samra · The University of Sydney2 papers (2018–2023)Victoria Bray · Camden and Campbelltown Hospitals2 papers (2021–2023)Anubhav Mittal · University of Technology Sydney2 papers (2018–2023)Prunella Blinman · The University of Sydney2 papers (2021–2021)José Luis Leal · Massachusetts Department of Mental Health2 papers (2021–2021)Jennifer Arena · Northern Sydney Local Health District2 papers (2018–2023)Bo Gao · Guiyang Medical University2 papers (2021–2021)Sarah Maloney · The University of Sydney1 papers (2023–2023)Angela Chou · Nepean Hospital1 papers (2018–2018)Rina Hui · The University of Sydney1 papers (2021–2021)Amy Sheen · Royal North Shore Hospital1 papers (2018–2018)Marliese Alexander · Medical University of South Carolina1 papers (2021–2021)David C. Currow · Migration Institute of Australia1 papers (2023–2023)Matthew Maddocks · Cicely Saunders International1 papers (2023–2023)Paul de Souza · Jaguar Land Rover (United Kingdom)1 papers (2021–2021)Sungwon Chang · University of Technology Sydney1 papers (2023–2023)